1 |
Chen MJ, Shimada T, Moulton AD, et al (1984). The functional human dihydrofolate reductase gene. J Biol Chem, 259, 3933-43.
|
2 |
Dervieux T, Greenstein N, Kremer J (2006). Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum, 54, 3095-103.
DOI
|
3 |
Dervieux T, Kremer J, Lein DO, et al (2004). Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics, 14, 733-9.
DOI
|
4 |
Evans WE, Relling MV (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-91.
DOI
ScienceOn
|
5 |
Fotoohi AK, Albertioni F (2008). Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma, 49, 410-26.
DOI
|
6 |
Galivan J, Ryan T, Rhee M, et al (1999). Glutamyl hydrolase: properties and pharmacologic impact. Semin Oncol, 26, 33-7.
|
7 |
Garcia-Bournissen F, Moghrabi A, Krajinovic M (2007). Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk Res, 31, 1023-5.
DOI
|
8 |
Genestier L, Paillot R, Quemeneur L, et al (2000). Mechanisms of action of methotrexate. Immunopharmacology, 47, 247-57.
DOI
|
9 |
Gorlick R, Goker E, Trippett T, et al (1996). Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med, 335, 1041-8.
DOI
|
10 |
Goto Y, Yue L, Yokoi A, et al (2001). A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res, 7, 1952-6.
|
11 |
Morandi C, Masters JN, Mottes M, et al (1982). Multiple forms of human dihydrofolate reductase messenger RNA. Cloning and expression in Escherichia coli of their DNA coding sequence. J Mol Biol, 156, 583-607.
DOI
|
12 |
Organista-Nava J, Gomez-Gomez Y, Saavedra-Herrera MV, et al (2010). Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leuk Res, 34, 728-32.
DOI
|
13 |
St Jude Children's Research Hospital (2005). St. Jude Total therapy XV: St Jude Children's Research Hospital, National Institutes of Health (NTH).
|
14 |
Panetta JC, Wall A, Pui CH, et al (2002). Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin Cancer Res, 8, 2423-9.
|
15 |
Relling MV, Dervieux T (2001). Pharmacogenetics and cancer therapy. Nat Rev Cancer, 1, 99-108.
DOI
|
16 |
Rhee MS, Lindau-Shepard B, Chave KJ, et al (1998). Characterization of human cellular gamma-glutamyl hydrolase. Mol Pharmacol, 53, 1040-6.
|
17 |
US Department of Health and Human Services (2009). Common terminology criteria for adverse events version 4.0 (CTCAE): U.S. Department of Health and Human services, National Institutes of Health, National Cancer Institute.
|
18 |
Yao R, Schneider E, Ryan TJ, et al (1996). Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro. Proc Natl Acad Sci USA, 93, 10134-8.
DOI
|
19 |
Yin D, Chave KJ, Macaluso CR, et al (1999). Structural organization of the human gamma-glutamyl hydrolase gene. Gene, 238, 463-70.
DOI
|
20 |
Chabner BA, Allegra CJ, Curt GA, et al (1985). Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest, 76, 907-12.
DOI
|
21 |
Chave KJ, Auger IE, Galivan J, et al (2000). Molecular modeling and site-directed mutagenesis define the catalytic motif in human gamma -glutamyl hydrolase. J Biol Chem, 275, 40365-70.
DOI
|
22 |
Chave KJ, Ryan TJ, Chmura SE, et al (2003). Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene, 319, 167-75.
DOI
|